Abstracts tagged "Biomarkers"

Abstract Number: 2668 • ACR Convergence 2024
Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome
Silvia Cavalli¹, Fabricio Espinosa-Ortega², Ryan A. Adams³, Lauren Guy³, Charlotta Preger⁴, Càtia Fernandes-Cerqueira⁵, Roberto Caporali⁶, Ingrid Lundberg⁷ and Antonella Notarnicola⁸, ¹University of Milan, Milan, Milan, Italy, ²Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³aTyr Pharma, 3545 John Hopkins Court, Suite 250, San Diego, CA, ⁴Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet;5Structural Genomics Consortium, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁵4Dcell, Montrueil, Ile-de-France, France, ⁶Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁷Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: The anti-Jo1 autoantibody (aJo1), targeting the histidyl-tRNA synthetase (HisRS) protein, is the most common diagnostic biomarker of the anti-synthetase syndrome (ASSD). So far, conflicting…
Abstract Number: 0066 • ACR Convergence 2024
Association Between Gut Microbiota, Inflammation, and Epigenetics in Rheumatoid Arthritis Patients
jose Manuel Lisbona-Montañez¹, Arkaitz Mucientes², Patricia Ruiz-Limón³, Gracia María Martín-Nuñez⁴, Rocio Redondo-Rodríguez⁴, Laura Cano-García⁴, Sara Manrique-Arija⁵, Isabel Moreno-Indias², Natalia Mena Vázquez⁶ and Antonio Fernández-Nebro⁷, ¹University of Malaga, Malaga, Andalucia, Spain, ²IBIMA Plataforma BIONAND, Malaga, Andalucia, Spain, ³IBIMA, Instituto de Biomedicina de Málaga, Cordoba, Spain, ⁴IBIMA Plataforma Bionand, Malaga, Spain, ⁵Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ⁶IBIMA, Málaga, Andalucia, Spain, ⁷Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain
Background/Purpose: The etiology of rheumatoid arthritis (RA) is not entirely known. Epigenetic modifications could be the link between genetic and environmental factors related to the…
Abstract Number: 0392 • ACR Convergence 2024
Evaluation for the Presence of Antibodies to Malondialdehyde-Acetaldehyde Adduct in Juvenile Idiopathic Arthritis and Its Subtypes
Geoffrey Thiele¹, Panteha Hayati Rezvan², Michal Cidon², Carlos Hunter³, Michael Duryee³, Ted Mikuls³ and Geoffrey Thiele³, ¹Children's Hospital of Los Angeles, Omaha, NE, ²Children's Hospital of Los Angeles, Los Angeles, CA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Studies of rheumatoid arthritis (RA) have shown that malondialdehyde-acetaldehyde (MAA) protein adducts and anti-MAA immune responses play a pathogenic role in disease progression. Expression of…
Abstract Number: 0524 • ACR Convergence 2024
Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers
Laura Galindo Domínguez¹, Belen Acasuso², Vanesa Balboa-Barreiro³, Juan Fernández-Tajes², Juan Cañete⁴, Benjamin Fernández-Gutiérrez⁵, Isidoro González-Álvaro⁶, José L Pablos⁷, Carmen Bejerano-Herreria⁸, Maite Silva-Díaz⁹, Franciso javier De-Toro-Santos², Natividad Oreiro¹⁰ and francisco J Blanco¹¹, ¹Instituto de Investigacion Biomedica de A Coruña (INIBIC), A Coruña, Spain, ²Unidad de Investigacion Clinica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas., Investigation, A Coruña, Spain, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁴Hospital Clinic an IDIBAPS, Barcelona, Spain, ⁵3Rheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, s/n, 28040, Madrid, Spain., Rheumatology, Madrir, Spain, Madrid, Madrid, Spain, ⁶University Hospital La Princesa, Madrid, Madrid, Spain, ⁷Health ministry, Madrid, Madrid, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁰CHUAC, La Coruna, Galicia, Spain, ¹¹INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: Reducing the dosage of biologic drugs in patients with rheumatoid arthritis (RA) who have achieved remission is a viable and necessary strategy. To identify…
Abstract Number: 0666 • ACR Convergence 2024
Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
Cuiling Fan¹, Shixian Chen² and Juan Li¹, ¹Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic), ²Nanfang Hospital, Southern Medical University, guangzhou, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
Abstract Number: 0803 • ACR Convergence 2024
Serum Adipokines and Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort
Anna Haggart¹, Joshua Baker², Tate Johnson³, Yangyuna Yang³, Punyasha Roul⁴, Katherine Wysham⁵, grant Cannon⁶, Gary Kunkel⁷, Dana Ascherman⁸, Paul Monach⁹, Gail Kerr¹⁰, Andreas Reimold¹¹, Michael Duryee³, Geoffrey Thiele³, Ted Mikuls³ and Bryant England³, ¹University of Nebraska Medical Center, Omaha, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴UNMC, Omaha, NE, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Dallas VA Medical Center, Dallas, TX
Background/Purpose: Adipokines are metabolic cytokines shown to be dysregulated in RA and prognostic of RA-related complications such as cardiovascular disease. Similarly, aberrations in adipokines have…
Abstract Number: 0906 • ACR Convergence 2024
Proteomic Signatures of Difficult-to-Treat Rheumatoid Arthritis: Identifying Predictive Biomarkers
Klára Mocová¹, Jiri Baloun¹, Aneta Prokopcová², Kristýna Brábníková Marešová¹, Herman Mann³, Jiří Vencovský², Karel Pavelka⁴ and Ladislav Šenolt², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Revmatologický ústav, Praha, Czech Republic, ⁴Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction and extra-articular manifestations. Despite the advancements in the…
Abstract Number: 1222 • ACR Convergence 2024
Large Language Model-driven Sentiment Analysis for Facilitating Fibromyalgia Diagnosis
Vincenzo Venerito and Florenzo Iannone, Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy
Background/Purpose: Fibromyalgia (FM) is a complex disorder with widespread pain and emotional distress, posing diagnostic challenges. FM patients show altered cognitive and emotional processing, with…
Abstract Number: 1490 • ACR Convergence 2024
Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
Vasileios Kyttaris¹, Andrew Concoff², Touba Warsi³, Sepehr Taghavi³, Sudha Kumar³, Stanley Park³, Abigail Patalinghug³, Christine Schleif³, Brittany Partain⁴, Joseph Ahearn⁵, Nicole Wilson⁶, Chau-Ching Liu⁶, Susan Manzi⁶ and Tyler O'Malley⁷, ¹BIDMC, Boston, MA, ²Exagen, Inc., Los Angeles, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Allegheny Health Network, Wexford, PA, ⁶Allegheny Health Network, Pittsburgh, PA, ⁷Exagen, Vista, CA
Background/Purpose: Conventional SLE diagnostic markers lack sensitivity and are biased towards severe disease, resulting in a subset of clinically ambiguous ANA-positive but specific autoantibody-negative patients.…
Abstract Number: 1709 • ACR Convergence 2024
Sex Differences in Serum Proteomic Profiles of Males and Females with Psoriatic Arthritis
Steven Dang¹, Xianwei Li², Liqun Diao², Joan Wither³, Igor Jurisica⁴, Vinod Chandran⁵ and Lihi Eder⁶, ¹Women's College Hospital, Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) affects males and females equally, but differences exist in the clinical presentation and treatment response. The biological mechanisms driving these differences…
Abstract Number: 2048 • ACR Convergence 2024
Prognostic Value of Bronchoalveolar Lavage in CTD-related Interstitial Lung Disease: An Observational Study
Maximilian Gysan¹, Svitlana Pochepnia², Helmut Prosch², Antje Lehmann¹, Silvia Lee¹, Andreas Renner¹, Daniela Gompelmann³, Marco Idzko¹, Iris Aykara⁴, Karolina Anderle⁴, Peter Weber⁴, Hans Kiener⁴, Michael Bonelli⁴, Daniel Mrak⁴, Daniel Aletaha⁵, Helga Lechner-Radner⁴ and Kastriot Kastrati⁴, ¹Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ²Division of General and Paediatric Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ³Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria., Vienna, Austria, ⁴Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁵Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria
Background/Purpose: The prognostic value of bronchoalveolar lavage (BAL) in connective tissue disease-related interstitial lung disease (CTD-ILD) is currently underexplored, resulting in a lack of understanding…
Abstract Number: 2294 • ACR Convergence 2024
Pharmacodynamic Effects of Nipocalimab on Disease Biomarkers in Patients with Moderate-to-Severe Active Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2 Study
Kathy Sivils¹, Steven Leonardo², He Li³, Keying Ma⁴, Matthew J. Loza⁵, Jonathan J. Hubbard⁴, Kim Campbell⁴ and Sheng Gao⁴, ¹Johnson & Johnson Innovative Medicine, Edmond, OK, ²Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA, ³Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁴Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁵Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, USA, Spring House, PA
Background/Purpose: Nipocalimab is a fully human, immunoglobulin G (IgG) 1 monoclonal antibody that selectively binds to the IgG-binding site of the neonatal crystallizable fragment receptor…
Abstract Number: 2487 • ACR Convergence 2024
Comparing Circulating Protein Profiles in Patients with Active Myeloperoxidase (MPO) vs Proteinase-3 (PR3) Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
Colebrook Johnson¹, David O'Dea¹, Natalie Atallah¹, Gary Reynolds¹, Bohang Jiang¹, Shruthi Srivatsan¹, Zachary Williams¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA
Background/Purpose: ANCA type (e.g., PR3-, MPO-ANCA) may be a better way to subgroup patients with ANCA-associated vasculitis (AAV) than phenotype (e.g., granulomatosis with polyangiitis [GPA]).…
Abstract Number: 2669 • ACR Convergence 2024
Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies
Hannah Bulgart¹, Kassidy Banford², Shane Bruckner³, Kevin McElhanon², Nicholas Young¹, Brian Paleo², Eric Beck², Rohit Aggarwal⁴, Chester Oddis⁵, Braden Zeno⁶, Wael Jarjour⁷ and Noah Weisleder³, ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University, Columbus, ³Ohio State University, Columbus, OH, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Ohio State University, upper arlington, OH, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Idiopathic immune myopathies (IIMs) are a group of autoimmune diseases that produce chronic inflammation and degeneration of skeletal muscle structure and function. One process…
Abstract Number: 0067 • ACR Convergence 2024
Psoriasis Patients at Risk for Psoriatic Arthritis Have Increased Levels of Circulating Pro-migratory Dendritic Cells
Shashank Cheemalavagu, Unnikrishnan Chandrasekharan, Oliver Wessely, Uyen Tran and M. Elaine Husni, Cleveland Clinic, Cleveland, OH
Background/Purpose: Early diagnosis of Psoriatic Arthritis (PsA) is critical for timely intervention to prevent poor clinical outcomes. Despite well-known clinical predictors of PsA, the mechanisms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].